Close Menu

SAN FRANCISCO (GenomeWeb) – After graduating from Illumina's Accelerator program in 2015 and raising $6 million in a Series A financing round last year, EpiBiome is working on harnessing genomic technology to develop phage-based therapies for bacterial infections.

The South San Francisco, California-based firm has 25 full-time employees and has also received $300,000 in funding from the Gates Foundation and US Department of Defense to use genomics to identify bacterial resistance pathways, as well as factors that make bacteria less pathogenic.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies.